Compare Alcon AG (ALC) vs JPMorgan Equity Premium Income ETF (JEPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs JPMorgan Equity Premium Income ETF — how do they compare? Alcon AG trades at $73.37 (market cap $36.44B), while JPMorgan Equity Premium Income ETF trades at $57.85. The key difference: Alcon AG pays a 0.48% dividend while JPMorgan Equity Premium Income ETF pays none, and JPMorgan Equity Premium Income ETF is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | JEPI | |
|---|---|---|
Market Cap | $36.44B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $90.12 | $59.88 |
52-Week Low | $62.02 | $55.29 |
Enterprise Value | $40.28B | — |
Dividend Yield | 0.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $73.59, down slightly by 0.05% today, with a bullish technical signal from moving averages and a consensus analyst price target of $86.67 implying 17.8% upside. Recent Q2 2026 earnings beat estimates with EPS of $0.84 versus $0.77 expected, and the company raised its 2026 profitability outlook, driving positive investor sentiment. Revenue growth has been steady, reaching $10.40 billion in 2025, though net income margin dipped to 5.92%.
The outlook is positive given strong earnings beats, raised guidance, and bullish analyst ratings, but risks include elevated P/E of 57.52, high RSI levels suggesting overbought conditions, and margin pressures from rising costs. Institutional ownership trends and recent collaborations, like with RxSight, support growth, yet macroeconomic and competitive factors warrant caution.
JEPI trades at $57.86, up 0.37% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The ETF focuses on generating income through covered calls, offering monthly dividends, though recent news highlights underperformance versus peers and tax inefficiencies. Key support and resistance cluster around $58.
Outlook is mixed: JEPI provides steady income attractive to retirees, but faces competition from higher-yielding alternatives and potential opportunity cost from capped upside. Risks include yield compression, tax treatment of distributions, and active management underperformance. Investors should weigh income needs against total return potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →
